Company · OCUL
Ocular Therapeutix, Inc.
Name as listed on its exchange; filed with the SEC as OCULAR THERAPEUTIX, INC.
Nasdaq's symbol directory lists OCUL on Nasdaq as “Ocular Therapeutix, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 9 occasions ($799K); 4 planned-sale notices; 3 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 45
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Dugel Pravin, Executive Chairman, President and CEO sold $233K
- Saroj Namrata, Chief Business Officer sold $232K
- Heier Jeffrey S., Chief Scientific Officer sold $112K
- Kaiser Peter, Chief Development Officer sold $103K
- Anderman Todd, Chief Legal Officer sold $87K
- Nayak Sanjay, Chief Strategy Officer sold $20K
- Notman Donald, Chief Operating Officer sold $11K
Every trade (9)
- SELLSaroj Namrata, Chief Business Officer sold $232K
- SELLAnderman Todd, Chief Legal Officer sold $87K
- SELLHeier Jeffrey S., Chief Scientific Officer sold $77K
- SELLKaiser Peter, Chief Development Officer sold $70K
- SELLNotman Donald, Chief Operating Officer sold $11K
- SELLDugel Pravin, Executive Chairman, President and CEO sold $233K
- SELLHeier Jeffrey S., Chief Scientific Officer sold $36K
- SELLKaiser Peter, Chief Development Officer sold $33K
- SELLNayak Sanjay, Chief Strategy Officer sold $20K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- NAMRATA SAROJ $232K
- TODD ANDERMAN $87K
- JEFFREY S. HEIER $77K
- PETER KAZUO KAISER $70K
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Departure or appointment of directors or officers Nov 9, 2026
- Results of operations and financial condition Nov 9, 2026
- Departure or appointment of directors or officers Oct 16, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.